Secondary Central Nervous System Lymphoma Clinical Trial
Official title:
Phase II Study of Zanubrutinib in Combination With Rituximab and Methotrexate, Followed by Zanubrutinib Maintenance in Patients With Secondary Central Nervous System Lymphoma (SCNSL)
Secondary central nervous system lymphoma (SCNSL) occurred in about 5% of patients with diffuse large B-cell lymphoma (DLBCL). The prognosis of SCNSL is very poor. A number of retrospective studies have shown that the median overall survival (mOS) since the diagnosis of CNSL is only 2.5-3.5 months, and the 2-year OS rate is only 20%. At present, there is no consensus on the treatment of SCNSL, and new therapeutic strategies are urgently needed. Zanubrutinib is a new second-generation BTK inhibitor, which has showed good efficacy and safety in a variety of B-NHL. Zanubrutinib has showed good blood-brain barrier permeability in preclinical studies. This study attempts to evaluate the efficacy and safety of zanubrutinib combined with rituximab and high-dose methotrexate in the treatment of SCNSL in patients with DLBCL.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04457869 -
A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)
|
Phase 2 | |
| Recruiting |
NCT05351593 -
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03964090 -
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
|
Phase 2 | |
| Active, not recruiting |
NCT04438044 -
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
|
Phase 2 | |
| Recruiting |
NCT05011045 -
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
|
||
| Recruiting |
NCT05256641 -
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05485753 -
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05681195 -
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
|
Phase 2 |